Views & Analysis Pharma 2022: big pharma will remain a constant Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
News Novo highlights key 'hypo' data from Tresiba at EASD Novo hopes data will justify higher price compared with rival.
News AZ talks up Bydureon data, GLP-1 and glucagon combo AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug.
News Teva appoints Lundbeck's Kare Schultz as CEO Unlike AZ's Soriot, Schultz "couldn't refuse" top job at Teva.
News FDA grants fast review for Roche's haemophilia drug Emicizumab is firm's latest blockbuster hopeful
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
